Find policies, billing codes, payers, states, and providers
HCPCS J2350: Ocrelizumab Injection, 1 mg
HCPCS Level II code J2350 designates the administration unit for ocrelizumab 1 mg, a monoclonal antibody used in neurologic disease management. As a drug-specific HCPCS code, J2350 is central to billing for infusion-based biologic therapy administered in outpatient infusion centers and hospital outpatient departments. Accurate use of this code supports consistent reimbursement, inventory tracking, and clinical documentation for high-cost specialty therapies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find a concise review of clinical context for J2350, typical sites of service, common companion administration codes, and the set of payers whose coverage policies most often affect payment outcomes. The publication outlines benchmarking elements relevant to billing and coding for intravenous biologic agents, summarizes coding relationships with administration procedure codes, and highlights ICD-10 diagnoses commonly associated with ocrelizumab use.
This national-level summary is intended for revenue cycle, coding professionals, and clinical managers who need a clear reference for the clinical and billing identity of J2350, the payers commonly encountered, and the coding context required for infusion-based monoclonal antibody therapy.
Customize your policy alerts
Sign up for hcpcs J2350 policy alerts
Get alerted when payer policies referencing J2350 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J2350 represents an injection of ocrelizumab, dosed at 1 mg per unit. This code is used to report the drug component of an intravenous monoclonal antibody therapy intended for neurologic indications. The service type is a drug administration (intravenous biologic therapy), and the typical site of service is an outpatient infusion center or hospital outpatient department.
National Reimbursement Benchmarks
National commercial reimbursement for HCPCS J2350 centers around the BUCA average commercial rate of $391.40, which provides a useful midpoint against individual payer distributions. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $6.90, Cigna’s spread is $0.30, UnitedHealth Group’s spread is $5.40, Aetna’s spread is $44.30, and BUCA’s spread is $12.20. These spreads indicate Cigna and Blue Cross Blue Shield exhibit the tightest concentration around their midpoints, while Aetna shows a markedly wider dispersion driven by outlier high values that push its P75–P25 range well above peers.
Comparing central tendency and dispersion, UnitedHealth Group and Blue Cross Blue Shield cluster near the low- to mid-$60s for medians and P50 values, while Cigna sits essentially at $59.40 as its median. Aetna’s very large maximum and broader spread contrast with the steadier patterns at Cigna and Blue Cross Blue Shield; BUCA’s average at $391.40 sits above most payer means but with a moderate interquartile range, reflecting higher overall commercial pricing with less extreme variability than Aetna.